-
Ajugol, Mitophagy, and Pyroptosis in Gouty Arthritis
2026-09-01
This study identifies impaired PINK1/Parkin-dependent mitophagy as a mechanistic link between PI3K/AKT/mTOR signaling and chondrocyte pyroptosis in acute gouty arthritis. Using computational prediction, cellular validation, pathway perturbation, and a mouse model, the authors show that ajugol reduces mitochondrial stress, inflammatory cell death, and cartilage injury, although clinical translation remains preliminary.
-
Resiniferatoxin (RTX): TRPV1 Research Guide
2026-09-01
Resiniferatoxin (RTX) is an ultra-potent TRPV1 agonist that produces sustained cation influx followed by sensory-neuron desensitization. Its research value spans pain, neurogenic inflammation, and route-specific translational models, but immune-context findings show why agonist effects require controlled interpretation.
-
A40926 Production Tools in Nonomuraea
2026-08-31
Yushchuk and colleagues developed promoter-probe and regulatory overexpression tools for the genetically recalcitrant glycopeptide producer Nonomuraea gerenzanensis. Their results show that strengthening pathway-specific positive regulation can increase A40926 production and provide a knowledge-based route to strain improvement at bioreactor scale.
-
Mianserin HCl: From 5-HT2 Biology to Translation
2026-08-31
Mianserin HCl is more than a legacy tetracyclic antidepressant: it is a mechanistic probe for noradrenergic and serotonergic biology, a platform for studying cyclodextrin-driven changes in cytotoxicity, and a potential bridge between psychiatric disorder research and antipathogenic investigation. This article outlines how translational teams can use its receptor pharmacology, formulation behavior, and exposure context to design more informative experiments.
-
Mianserin HCl: Designing Better Mechanistic Assays
2026-08-30
Mianserin HCl is more than a historical antidepressant: it is a useful perturbation tool for separating receptor-driven effects from sedation, exposure, and formulation variables. This article translates placebo-controlled clinical evidence into practical assay design for serotonin signaling and psychiatric disorder research.
-
(S)-Mephenytoin as a CYP2C19 Substrate
2026-08-29
(S)-Mephenytoin is a defined CYP2C19 substrate for studying oxidative drug metabolism and anticonvulsive drug metabolism. Its reported hydroxylation kinetics support assay benchmarking, while hiPSC-derived intestinal organoids provide a human-relevant model that still requires direct validation for CYP2C19 activity.
-
Streptavidin-Cy3 for Biohybrid Microrobot Assays
2026-08-28
Turn biotinylated antibodies and nucleic-acid probes into spatial readouts for Euglena-based biohybrid microrobot studies, from tumor spheroids to dense three-dimensional matrices. This workflow pairs Cy3 spectral guidance with practical controls and titration for IHC, IF, ISH, and flow cytometry without overstating what the reference study demonstrated.
-
Tomivosertib Suppresses Human DRG Ectopic Activity
2026-08-28
The reference study provides direct human-neuron evidence that MNK inhibition with tomivosertib reversibly suppresses spontaneous activity in cultured dorsal root ganglion neurons obtained from patients with radiculopathy. Rapid loss of eIF4E Ser209 phosphorylation and changes in sodium- and potassium-channel-linked electrophysiological features support MNK signaling as a mechanistically relevant target for neuropathic pain research.
-
Coelenterazine for Interpreting ROS Reporter Signals
2026-08-27
Coelenterazine is a luminescent enzyme substrate for connecting reporter activity with reactive oxygen species chemistry. This article presents an orthogonal assay framework inspired by brain–kidney AVP research, emphasizing signal provenance, controls, and translational limits.
-
Aztreonam Workflows for Gram-Negative Research
2026-08-27
Aztreonam supports more than routine growth-inhibition assays: it can connect Gram-negative resistance phenotyping with bone marrow and hepatic drug-metabolism research. This workflow-focused guide covers preparation, assay design, interpretation, and troubleshooting while keeping the evidence boundaries clear.
-
BHQ: From SERCA Mechanism to Translation
2026-08-26
2,5-di-tert-butylbenzene-1,4-diol (BHQ) offers a mechanistic route from SERCA inhibition and calcium-store depletion to ER stress and hematopoietic stem cell mobilization. This thought-leadership guide connects calcium biology with translational study design while defining the compound’s opportunities, controls, and limitations.
-
(S)-Mephenytoin in Human CYP2C19 Translation
2026-08-26
Translational pharmacokinetics requires more than a clean enzyme assay: it requires a mechanistic bridge from catalytic activity to intestinal absorption, metabolism, and interindividual variability. This article positions (S)-Mephenytoin as a defined CYP2C19 substrate for building that bridge, then shows how recombinant systems, human pluripotent stem cell-derived intestinal organoids, and orthogonal analytical controls can be combined into a more decision-ready workflow.
-
URB597 (KDS-4103): Selective FAAH Inhibition
2026-08-25
URB597, also called KDS-4103, is a potent and selective FAAH inhibitor for experimental endocannabinoid research. It increases anandamide availability by blocking FAAH activity, with reported subnanomolar-to-low-nanomolar potency in neuronal systems and rapid in vivo FAAH inhibition in rats.
-
hiPSC Intestinal Organoids for Pharmacokinetic Studies
2026-08-25
Saito and colleagues established a direct three-dimensional culture strategy for generating expandable intestinal organoids from human induced pluripotent stem cells. The organoids could be propagated, cryopreserved, and converted into two-dimensional intestinal epithelial monolayers containing metabolically active enterocytes, supporting more human-relevant pharmacokinetic studies.
-
Tianhuang Formula Targets RAGE/POMC in Metabolism
2026-08-24
This pre-proof study identifies RAGE as a central nervous system target of berberine within Tianhuang Formula and links RAGE/POMC signaling to hypothalamic neuronal apoptosis, autophagy, and glucolipid regulation. Its integrated computational, cellular, and mouse-model design provides a mechanistic framework for testing how neuronal homeostasis contributes to metabolic disease, while broader applications to neurodegeneration remain preliminary.